Literature DB >> 29556866

Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods.

Jingtao Lu1, Jianguo Li1, Gabriel Helmlinger1, Nidal Al-Huniti2.   

Abstract

Modeling the relationship between drug concentrations and heart rate corrected QT interval (QTc) change from baseline (C-∆QTc), based on Phase I single ascending dose (SAD) or multiple ascending dose (MAD) studies, has been proposed as an alternative to thorough QT studies (TQT), in assessing drug-induced QT prolongation risk. The present analysis used clinical SAD, MAD and TQT study data of an experimental compound, AZD5672, to evaluate the performance of: (i) three computational platforms (linear mixed-effects modeling implemented via PROC MIXED in SAS, as well as in R using LME4 package and linear quantile mixed models (LQMM) implemented via LQMM package; (ii) different model structures with and without treatment- or time-specific intercepts; and (iii) three methods for calculating the confidence interval (CI) of QTc prolongation (analytical and bootstrap methods with fixed or varied geometric mean concentrations). We show that treatment- and time-specific intercepts may need to be included into C-∆QTc modeling through PROC MIXED or LME4, regardless of their statistical significance. With the intersection union test (IUT) in the TQT study as a reference for comparison, inclusion of these intercepts increased the feasibility for C-∆QTc modelling of SAD or MAD to reach the same conclusion as the IUT analysis based on TQT study. Compared to PROC MIXED or LME4, the LQMM method is less dependent on inclusion of treatment- or time-specific intercepts, and the bootstrap CI calculation methods provided higher likelihood for C-∆QTc modeling of SAD and MAD studies to reach the same conclusion as the IUT based on the TQT study.

Entities:  

Keywords:  AZD5672; C-∆QTcF modeling; Linear mixed-effects model; Linear quantile mixed model; Multiple-ascending dose study; QTc interval prolongation; Single-ascending dose study; Thorough QT/QTc study

Mesh:

Substances:

Year:  2018        PMID: 29556866     DOI: 10.1007/s10928-018-9582-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  32 in total

Review 1.  Individual patterns of QT/RR relationship.

Authors:  Velislav Batchvarov; Marek Malik
Journal:  Card Electrophysiol Rev       Date:  2002-09

2.  A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients.

Authors:  J Florian; C E Garnett; S C Nallani; B A Rappaport; D C Throckmorton
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

Review 3.  The IQ-CSRC prospective clinical Phase 1 study: "Can early QT assessment using exposure response analysis replace the thorough QT study?".

Authors:  Borje Darpo; Nenad Sarapa; Christine Garnett; Charles Benson; Corina Dota; Georg Ferber; Venkateswar Jarugula; Lars Johannesen; James Keirns; Kevin Krudys; Catherine Ortemann-Renon; Steve Riley; Danise Rogers-Subramaniam; Norman Stockbridge
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-12-30       Impact factor: 1.468

4.  Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.

Authors:  Shashank Rohatagi; Timothy J Carrothers; Jon Kuwabara-Wagg; Tatiana Khariton
Journal:  J Clin Pharmacol       Date:  2009-09-04       Impact factor: 3.126

5.  Modelling PK/QT relationships from Phase I dose-escalation trials for drug combinations and developing quantitative risk assessments of clinically relevant QT prolongations.

Authors:  Karen Sinclair; Els Kinable; Kai Grosch; Jixian Wang
Journal:  Pharm Stat       Date:  2016-03-17       Impact factor: 1.894

6.  Development of QTc prolongation model incorporating circadian rhythm using harmonic model.

Authors:  Hyun-moon Back; Jong-Hwa Lee; Hwi-yeol Yun; Kwang-il Kwon
Journal:  Xenobiotica       Date:  2014-12-05       Impact factor: 1.908

7.  Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant.

Authors:  Patricia J Murphy; Sanae Yasuda; Kenya Nakai; Takashi Yoshinaga; Nancy Hall; Meijian Zhou; Jagadeesh Aluri; Bhaskar Rege; Margaret Moline; Jim Ferry; Borje Darpo
Journal:  J Clin Pharmacol       Date:  2016-08-04       Impact factor: 3.126

8.  Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839.

Authors:  Erik Sparve; Angelica L Quartino; Maria Lüttgen; Karin Tunblad; Anna Teiling Gårdlund; Johanna Fälting; Robert Alexander; Jens Kågström; Linnea Sjödin; Alexander Bulgak; Ahmad Al-Saffar; Matthew Bridgland-Taylor; Chris Pollard; Michael D B Swedberg; Torbjörn Vik; Björn Paulsson
Journal:  J Pharmacol Exp Ther       Date:  2014-06-10       Impact factor: 4.030

9.  Linear mixed-effects model of QTc prolongation for olmesartan medoxomil.

Authors:  SaeHeum Song; Nobuko Matsushima; James Lee; Jeanne Mendell
Journal:  J Clin Pharmacol       Date:  2015-08-24       Impact factor: 3.126

10.  Evaluating the Use of Linear Mixed-Effect Models for Inference of the Concentration-QTc Slope Estimate as a Surrogate for a Biological QTc Model.

Authors:  Y Huh; M M Hutmacher
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-01-28
View more
  3 in total

1.  Thorough QT/QTc in a Dish: An In Vitro Human Model That Accurately Predicts Clinical Concentration-QTc Relationships.

Authors:  Alexander D Blanchette; Fabian A Grimm; Chimeddulam Dalaijamts; Nan-Hung Hsieh; Kyle Ferguson; Yu-Syuan Luo; Ivan Rusyn; Weihsueh A Chiu
Journal:  Clin Pharmacol Ther       Date:  2018-12-02       Impact factor: 6.875

2.  Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure-response analysis.

Authors:  Nikolaos Tsamandouras; Sridhar Duvvuri; Steve Riley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-10-29       Impact factor: 2.745

3.  Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations.

Authors:  Veronika Voronova; Marie Cullberg; Philip Delff; Joanna Parkinson; Corina Dota; Gaia Schiavon; Brijesh Maroj; Dinko Rekić; S Y Amy Cheung
Journal:  Br J Clin Pharmacol       Date:  2021-09-28       Impact factor: 3.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.